Retatrutide's Phase 2 trial data (Jastreboff et al., NEJM 2023) identified a side-effect profile broadly consistent with other incretin-based therapies: Gastrointestinal : Nausea, vomiting, diarrhoea, and constipation were the most commonly reported adverse effects, particularly during dose escalation
References Therapeutic Goods Administration
Using a L-5-methyltetrahydrofolate instead of folic acid, and ensuring we have optimal B12 in the form of methylcobalamin, and vitamin B6 in P-5-P form are key in helping with these pathways
Currently, the following drugs are approved for long-term treatment of obesity worldwide: Orlistat (Xenical, Xenical, Roche, Basel, Switzerland), 1999
BPC 157 Peptide is Anti-Inflammatory Beyond its gastrointestinal applications, BPC 157 also exhibits powerful anti-inflammatory properties